Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination Therapy For Treatment Of Disease

Inactive Publication Date: 2016-06-23
ONCOMED PHARMA
View PDF3 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods for treating diseases such as cancer by combining a Notch pathway inhibitor with an immunotherapy agent. This combination therapy may offer advantages such as improved efficacy, lower dosages, reduced side effects, and increased likelihood of response. The methods may also involve identifying if a patient should receive the combination therapy based on the expression level of PD-L1 in a sample. Overall, the invention provides a valuable tool for treating cancer and related diseases.

Problems solved by technology

Combination therapy with at least two therapeutic agents often uses agents that work by different mechanisms of action, and / or target different pathways and may result in additive or synergetic effects.
Combination therapy may decrease the likelihood that resistance to an agent will develop.
In addition, the order and / or timing of the administration of each therapeutic agent may affect the overall efficacy of a drug combination.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination Therapy For Treatment Of Disease
  • Combination Therapy For Treatment Of Disease
  • Combination Therapy For Treatment Of Disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Anti-DLL4 Antibody on PD-1 Expression in Cells from CT26.WT Tumors

[0326]The murine colon carcinoma CT26.WT was obtained from ATCC. CT26.WT cells were injected subcutaneously into the rear flanks of 6-8 week old Balb / C mice. Tumors were allowed to grow until they reached an average size of 200 mm3. The mice were randomized into groups (n=10) and treated with anti-mouse DLL4 (mDLL4) antibody 21R30 (10 mg / kg, weekly), SIRPα-Fc protein (10 mg / kg, biweekly), or a control Fc protein (10 mg / kg, weekly). The agents were administered by injection into the intraperitoneal cavity. Fourteen days after the initial dose, the tumors were harvested and total protein was isolated from individual mice using tissue extraction buffer (Life Technologies). Proteins (20 μg) were resolved by SDS-PAGE gel electrophoresis, and Western blot analysis was performed using an anti-PD-1 antibody.

[0327]As shown in FIG. 1A, PD-1 expression in tumor cell lysates from mice treated with anti-mDLL4 antibody 21...

example 2

Effect of Mouse IL-2-Fc and Anti-mDLL4 Antibody on Tumor Growth

[0329]Murine colon carcinoma CT26.WT cells were injected subcutaneously into the flanks of 6-8 week old Balb / C mice. Tumors were allowed to grow to an average tumor volume of 100 mm3. The mice were randomized into groups (n=10) and treated with anti-mDLL4 antibody 21R30 (30 mg / kg, weekly), mIL-2-Fc protein (1 mg / kg, 5 days each week), or a combination of anti-mDLL4 antibody and mIL-2-Fc. An anti-GFP antibody and a murine Fc protein were used as controls for 21R30 and mIL-2-Fc, respectively. Agents were administered by intraperitoneal injection. Tumor growth was monitored and tumor volumes measured using electronic calipers at the indicated time points. The data are expressed as average tumor volume ±SEM.

[0330]As shown in FIG. 2A, anti-mDLL4 antibody 21R30 and mIL-2-Fc both inhibited CT26.WT tumor growth as single agents as compared to control. Furthermore, a combination of the anti-mDLL4 antibody and mIL-2-Fc inhibited t...

example 3

Cell Cytotoxicity Assays

[0337]For natural killer (NK) cytotoxicity assays, the mouse lymphoblast cell line YAC-1 and the mouse colon carcinoma cell line CT26.WT were cultured in RPMI 1640 culture medium (Gibco / Life Technologies, Grand Island, N.Y.) supplemented with 10% (v / v) fetal bovine serum (FBS), 2 mM L-glutamine, 100 U / ml penicillin, and 100 μg / ml streptomycin (Gibco) at 37° C. in a humidified atmosphere of 5% CO2. YAC-1 cells are known to be sensitive to NK cell activity and are a good target for NK cell assays.

[0338]Cells were harvested from the spleens of the CT26.WT tumor-bearing mice described above in Example 2. Cells were plated in 96-well V-bottom plates in RPMI 1640 culture medium (Gibco / Life Technologies, Grand Island, N.Y.) supplemented with 10% (v / v) fetal bovine serum (FBS), 2 mM L-glutamine, 100 U / ml penicillin, and 100 μg / ml streptomycin (Gibco). Target cells (YAC-1 or CT26.WT) were labeled with 10 μM calcein AM (Life Technologies) for 1 hour at 37° C. and then ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Therapeuticaaaaaaaaaa
Immunogenicityaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and / or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the priority benefit of U.S. Provisional Application No. 62 / 073,634, filed Oct. 31, 2014, U.S. Provisional Application No. 62 / 127,172, filed Mar. 2, 2015, U.S. Provisional Application No. 62 / 192,133, filed Jul. 14, 2015, and U.S. Provisional Application No. 62 / 242,567, filed Oct. 16, 2015, each of which is hereby incorporated by reference herein in its entirety.FIELD OF THE INVENTION[0002]The present invention provides methods comprising combination therapy for modulating immune responses and treating cancer and other diseases. In particular, the present invention provides Notch pathway inhibitors, including DLL4 antagonists and Notch receptor antagonists, in combination with at least one additional immunotherapeutic agent for the treatment of cancer.BACKGROUND OF THE INVENTION[0003]Cancer is one of the leading causes of death in the developed world, with over one million people diagnosed with cancer and 500,000 de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61K31/519A61K31/282A61K39/395
CPCC07K16/28A61K39/39558A61K31/519A61K31/282C07K16/2803A61K2039/572A61K2039/507C07K2317/24C07K2317/31C07K2317/76C07K16/2827A61P35/00A61P43/00A61K39/395A61K2300/00A61K39/3955A61K2039/505C07K14/475C12N15/11C12N15/113C12N15/1136C07K16/22C07K2317/565C07K2317/56
Inventor MURRIEL, CHRISTOPHER LAMONDHOEY, TIMOTHY CHARLESGURNEY, AUSTIN L.RODA, JULIE MICHELLESRIVASTAVA, MINU K.PARK, INKYUNGDUPONT, JAKOB
Owner ONCOMED PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com